FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W195540012> ?p ?o ?g. }

• W195540012 endingPage "140" @default.
• W195540012 startingPage "135" @default.
• W195540012 abstract "The evidence of lymphocytopenia has been demonstrated to predict a poor prognosis in terms of survival in advanced cancer patients. This finding is not surprising because of the fundamental role of lymphocytes in mediating tumor cell destruction. Despite the importance of lymphocytes in the pathogenesis of cancer, there are only few data about the profile and the function of lymphocytes during the various antitumor therapies, and in particular the relation between lymphocyte pretreatment number and response to chemotherapy remains to be established. The present study was performed to evaluate whether the evidence of lymphocytopenia before the onset of treatment may influence the efficacy of chemotherapy in metastatic cancer patients affected by the most frequent tumor types. The study included 183 patients (lung cancer: 89; colorectal cancer: 63; breast cancer: 31), 95 of whom had been previously treated with chemotherapy. The chemotherapeutic regimens consisted of oxaliplatin plus 5-fluorouracil and folates in untreated colorectal cancer, weekly irinotecan in pretreated colorectal cancer, cisplatin plus gemcitabine or etoposide in untreated lung cancer, weekly vinorelbine in pretreated lung cancer, and taxotere in breast cancer patients who had been previously treated with anthracyclines. Lymphocyte count was considered to be abnormally low for values below 1500/mm 3 . Lymphocytopenia was found in 79/183 (43%) patients, without any significant differences in relation to tumor histology. A complete response (CR) was achieved in 6/104 patients with a normal lymphocyte count and in none of the 79 lymphocytopenic patients. A partial response (PR) was obtained in 39 patients with a normal lymphocyte count and in only eight patients with a low lymphocyte count prior to therapy. Therefore, irrespective of the type of chemotherapy, the objective tumor response rate (CR + PR) in lymphocytopenic patients was significantly lower than in patients with normal pretreatment lymphocyte counts (8/79 vs 45/104; p<0. 001). This study shows that the evidence of lymphocytopenia prior to chemotherapy is associated with a lower efficacy of treatment in terms of objective tumor regression rates in patients with metastatic solid tumors, and suggests that the action of chemotherapy may depend at least in part on an interaction with the antitumor immunity. Pretreatment lymphocyte count may represent a new, simple biological marker to be taken into consideration by oncologists in the chemotherapeutic treatment of metastatic cancer." @default.
• W195540012 created "2016-06-24" @default.
• W195540012 creator A5020423134 @default.
• W195540012 creator A5024090764 @default.
• W195540012 creator A5026158008 @default.
• W195540012 creator A5031089579 @default.
• W195540012 creator A5037714306 @default.
• W195540012 creator A5042859107 @default.
• W195540012 creator A5048959631 @default.
• W195540012 creator A5052130645 @default.
• W195540012 creator A5064209449 @default.
• W195540012 creator A5077313404 @default.
• W195540012 date "2004-04-01" @default.
• W195540012 modified "2023-09-27" @default.
• W195540012 title "Efficacy of Cancer Chemotherapy in Relation to the Pretreatment Number of Lymphocytes in Patients with Metastatic Solid Tumors" @default.
• W195540012 cites W101858714 @default.
• W195540012 cites W1983273033 @default.
• W195540012 cites W1990078051 @default.
• W195540012 cites W2002724941 @default.
• W195540012 cites W2036275492 @default.
• W195540012 cites W2051962533 @default.
• W195540012 cites W2076363246 @default.
• W195540012 cites W2084557581 @default.
• W195540012 cites W2088391922 @default.
• W195540012 cites W2104439753 @default.
• W195540012 cites W2163796754 @default.
• W195540012 cites W2259178548 @default.
• W195540012 cites W2412992458 @default.
• W195540012 doi "https://doi.org/10.1177/172460080401900208" @default.
• W195540012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15255546" @default.
• W195540012 hasPublicationYear "2004" @default.
• W195540012 type Work @default.
• W195540012 sameAs 195540012 @default.
• W195540012 citedByCount "88" @default.
• W195540012 countsByYear W1955400122012 @default.
• W195540012 countsByYear W1955400122013 @default.
• W195540012 countsByYear W1955400122014 @default.
• W195540012 countsByYear W1955400122015 @default.
• W195540012 countsByYear W1955400122016 @default.
• W195540012 countsByYear W1955400122017 @default.
• W195540012 countsByYear W1955400122018 @default.
• W195540012 countsByYear W1955400122019 @default.
• W195540012 countsByYear W1955400122020 @default.
• W195540012 countsByYear W1955400122021 @default.
• W195540012 countsByYear W1955400122022 @default.
• W195540012 countsByYear W1955400122023 @default.
• W195540012 crossrefType "journal-article" @default.
• W195540012 hasAuthorship W195540012A5020423134 @default.
• W195540012 hasAuthorship W195540012A5024090764 @default.
• W195540012 hasAuthorship W195540012A5026158008 @default.
• W195540012 hasAuthorship W195540012A5031089579 @default.
• W195540012 hasAuthorship W195540012A5037714306 @default.
• W195540012 hasAuthorship W195540012A5042859107 @default.
• W195540012 hasAuthorship W195540012A5048959631 @default.
• W195540012 hasAuthorship W195540012A5052130645 @default.
• W195540012 hasAuthorship W195540012A5064209449 @default.
• W195540012 hasAuthorship W195540012A5077313404 @default.
• W195540012 hasConcept C121608353 @default.
• W195540012 hasConcept C126322002 @default.
• W195540012 hasConcept C143998085 @default.
• W195540012 hasConcept C203014093 @default.
• W195540012 hasConcept C2776256026 @default.
• W195540012 hasConcept C2776694085 @default.
• W195540012 hasConcept C2777761686 @default.
• W195540012 hasConcept C2777990475 @default.
• W195540012 hasConcept C2778119113 @default.
• W195540012 hasConcept C2778239845 @default.
• W195540012 hasConcept C2780258809 @default.
• W195540012 hasConcept C2780259306 @default.
• W195540012 hasConcept C2780350996 @default.
• W195540012 hasConcept C2780962732 @default.
• W195540012 hasConcept C526805850 @default.
• W195540012 hasConcept C530470458 @default.
• W195540012 hasConcept C71924100 @default.
• W195540012 hasConcept C90924648 @default.
• W195540012 hasConceptScore W195540012C121608353 @default.
• W195540012 hasConceptScore W195540012C126322002 @default.
• W195540012 hasConceptScore W195540012C143998085 @default.
• W195540012 hasConceptScore W195540012C203014093 @default.
• W195540012 hasConceptScore W195540012C2776256026 @default.
• W195540012 hasConceptScore W195540012C2776694085 @default.
• W195540012 hasConceptScore W195540012C2777761686 @default.
• W195540012 hasConceptScore W195540012C2777990475 @default.
• W195540012 hasConceptScore W195540012C2778119113 @default.
• W195540012 hasConceptScore W195540012C2778239845 @default.
• W195540012 hasConceptScore W195540012C2780258809 @default.
• W195540012 hasConceptScore W195540012C2780259306 @default.
• W195540012 hasConceptScore W195540012C2780350996 @default.
• W195540012 hasConceptScore W195540012C2780962732 @default.
• W195540012 hasConceptScore W195540012C526805850 @default.
• W195540012 hasConceptScore W195540012C530470458 @default.
• W195540012 hasConceptScore W195540012C71924100 @default.
• W195540012 hasConceptScore W195540012C90924648 @default.
• W195540012 hasIssue "2" @default.
• W195540012 hasLocation W1955400121 @default.
• W195540012 hasLocation W1955400122 @default.
• W195540012 hasOpenAccess W195540012 @default.
• W195540012 hasPrimaryLocation W1955400121 @default.

• next